Journal of Thoracic Oncology

Journal Information
ISSN / EISSN : 1556-0864 / 1556-1380
Current Publisher: Ovid Technologies (Wolters Kluwer Health) (10.1097)
Former Publisher: Elsevier BV (10.1016)
Total articles ≅ 18,710
Current Coverage
SCOPUS
PUBMED
MEDLINE
MEDICUS
SCIE
Archived in
SHERPA/ROMEO
Filter:

Latest articles in this journal

Anna Kron, Matthias Scheffler, Carina Heydt, Lea Ruge, Carsten Schaepers, Anna-Kristina Eisert, Sabine Merkelbach-Bruse, Richard Riedel, Lucia Nogova, Rieke Nila Fischer, et al.
Published: 1 April 2021
Journal of Thoracic Oncology, Volume 16, pp 572-582; doi:10.1016/j.jtho.2020.11.017

The publisher has not yet granted permission to display this abstract.
Vincent K. Lam, Jianjun Zhang, Carol C. Wu, Hai T. Tran, Lerong Li, Lixia Diao, Jing Wang, Waree Rinsurongkawong, Victoria M. Raymond, Richard B. Lanman, et al.
Published: 1 April 2021
Journal of Thoracic Oncology, Volume 16, pp 601-609; doi:10.1016/j.jtho.2020.12.011

The publisher has not yet granted permission to display this abstract.
, Fabrice Barlesi, Howard West, Simon Ball, Rodolfo Bordoni, Manuel Cobo, Pascale Dubray Longeras, Jerome Goldschmidt, Silvia Novello, Francisco Orlandi, et al.
Published: 1 April 2021
Journal of Thoracic Oncology, Volume 16, pp 653-664; doi:10.1016/j.jtho.2020.11.025

Abstract:
Introduction We report the final results of the phase 3 IMpower132 study evaluating atezolizumab plus carboplatin or cisplatin plus pemetrexed (APP) in patients with nonsquamous NSCLC. Methods Chemotherapy-naive patients with stage IV nonsquamous NSCLC without sensitizing EGFR or ALK genetic alterations were randomized in a one-to-one ratio to receive four or six cycles of carboplatin or cisplatin plus pemetrexed (PP) or APP every 3 weeks, followed by maintenance therapy with atezolizumab plus pemetrexed or pemetrexed alone. Co-primary end points were overall survival (OS) and investigator-assessed progression-free survival (PFS). Results The intention-to-treat population included 578 patients (APP, n = 292; PP, n = 286). At the primary PFS analysis (May 22, 2018; median follow-up, 14.8 mo), APP exhibited significant PFS improvement versus PP (median = 7.6 versus 5.2 mo, stratified hazard ratio [HR] = 0.60, 95% confidence interval [CI]: 0.49–0.72, p < 0.0001). OS for the APP group was numerically better but not statistically significant at the interim (May 22, 2018; median = 18.1 versus 13.6 mo, stratified HR = 0.81, 95% CI: 0.64–1.03, p = 0.0797) and final analyses (July 18, 2019; median = 17.5 versus 13.6 mo; stratified HR = 0.86, 95% CI: 0.71–1.06, p = 0.1546). The OS and PFS results favored APP versus PP across subgroups. Grade 3 or 4 treatment-related adverse events occurred in 54.6% (APP) and 40.1% (PP) of patients; grade 5 treatment-related events occurred in 3.8% and 2.9%, respectively. Conclusions IMpower132 met its co-primary PFS end point but not its co-primary OS end point, with numerical improvement for OS in the APP arm. APP had a manageable safety profile, with no new or unexpected safety signals identified.
, Stefan Michiels, Yu Shyr, Alex A. Adjei, Ann L. Oberg
Published: 1 April 2021
Journal of Thoracic Oncology, Volume 16, pp 537-545; doi:10.1016/j.jtho.2021.01.1616

Abstract:
Biomarkers have various applications including disease detection, diagnosis, prognosis, prediction of response to intervention, and disease monitoring. In this era of precision medicine, having validated biomarkers to inform clinical decision making is more important than ever. In this article, we discuss best the practices and potential issues in biomarker discovery and validation. We encourage team science partnerships to bring cutting-edge discovery from bench to bedside, leading to improved patient care and outcomes.
Yudai Tateishi, Nobuyuki Horita, Ho Namkoong, Tatsuji Enomoto, Atsuya Takeda, Takeshi Kaneko
Published: 1 April 2021
Journal of Thoracic Oncology, Volume 16, pp 677-685; doi:10.1016/j.jtho.2020.12.023

The publisher has not yet granted permission to display this abstract.
, Matthew P. Smeltzer, Nicholas R. Faris, Meredith A. Ray, Carrie Fehnel, Phillip Ojeabulu, Olawale Akinbobola, Meghan Meadows-Taylor, Laura M. McHugh, Ahmed M. Halal, et al.
Published: 1 April 2021
Journal of Thoracic Oncology, Volume 16, pp 630-642; doi:10.1016/j.jtho.2020.12.025

Abstract:
Introduction Suboptimal pathologic nodal staging prevails after curative-intent resection of lung cancer. We evaluated the impact of a lymph node specimen collection kit on lung cancer surgery outcomes in a prospective, population-based, staggered implementation study. Methods From January 1, 2014, to August 28, 2018, we implemented the kit in three homogeneous institutional cohorts involving 11 eligible hospitals from four contiguous hospital referral regions. Our primary outcome was pathologic nodal staging quality, defined by the following evidence-based measures: the number of lymph nodes or stations examined, proportions with poor-quality markers such as nonexamination of lymph nodes, and aggregate quality benchmarks including the National Comprehensive Cancer Network criteria. Additional outcomes included perioperative complications, health care utilization, and overall survival. Results Of 1492 participants, 56% had resection with the kit and 44% without. Pathologic nodal staging quality was significantly higher in the kit cases: 0.2% of kit cases versus 9.8% of nonkit cases had no lymph nodes examined; 3.2% versus 25.3% had no mediastinal lymph nodes; 75% versus 26% attained the National Comprehensive Cancer Network criteria (p < 0.0001 for all comparisons). Kit cases revealed no difference in perioperative complications or health care utilization except for significantly shorter duration of surgery, lower proportions with atelectasis, and slightly higher use of blood transfusion. Resection with the kit was associated with a lower hazard of death (crude, 0.78 [95% confidence interval: 0.61–0.99]; adjusted 0.85 [0.71–1.02]). Conclusions Lung cancer surgery with a lymph node collection kit significantly improved pathologic nodal staging quality, with a trend toward survival improvement, without excessive perioperative morbidity or mortality.
Published: 1 April 2021
Journal of Thoracic Oncology, Volume 16; doi:10.1016/s1556-0864(21)01757-3

Published: 1 April 2021
Journal of Thoracic Oncology, Volume 16; doi:10.1016/s1556-0864(21)01751-2

Published: 1 April 2021
Journal of Thoracic Oncology, Volume 16; doi:10.1016/s1556-0864(21)01755-x

Published: 1 April 2021
Journal of Thoracic Oncology, Volume 16, pp 493-500; doi:10.1016/j.jtho.2021.02.012

Back to Top Top